Cancer and immune response: Old and new evidence for future challenges

Oncologist

Volumn 13, Issue 12, 2008, Pages 1246-1254

  De La Cruz Merino, Luis ^a   Grande Pulido, Enrique ^b   Albero Tamarit, Ana ^a   De Villena, Manuel Eduardo Codes Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b PFIZER INC   (United States)

Author keywords

Cancer; Cancer vaccines; CTLA 4; GM CSF; IL 2; Immune tolerance; Tumor infiltrating lymphocytes

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PACLITAXEL; RITUXIMAB; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BREAST CANCER; CANCER MODEL; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 58749109167     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0166     Document Type: Review

References (55)

1. Himmelweit F, ed. The Collected Papers of Paul Ehrlich, Vol. 3. London: Pergamon, 1960:1-282.
2. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703.
3. Restifo NP, Robbins PF, Rosenberg SA. Principles of immunotherapy. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Eighth Edition. Philadelphia: Lippincott Williams & Wilkins, 2008:351-368.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10:909-915.
5. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002;2:514-520.
6. Ribas A, Butterfield LH, Glaspy JA et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-2432.
7. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: Moving beyond current paradigms. Clin Cancer Res 2007;13:3776 -3782.
8. Laheru D, Jafee E. Cancer vaccines. In: Wiley & Sons Ltd., eds. The Cancer Handbook, Second Edition. Chichester, UK: Wiley, 2007:1268-1274.
9. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
10. Kondratiev S, Sabo E, Yakirevich E et al. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450-4456.
11. Nagorsen D, Scheibenbogen C, Marincola FM et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-4303.
12. Piras F, Colombari R, Minerba L et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005;104:1246-1254.
13. Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576-2582.
14. + T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
15. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389-400.
16. Hori S, Nomura T, Sakaguchi S et al. Control of regulatory T cell development by the transcription factor FoxP3. Science 2003;299:1057-1061.
17. Vence L, Palucka AK, Fay JW et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007;104:20884-20889.
18. O'Garra A, Vieira PL, Vieira P et al. IL-10-producing and naturally occurring CD4+ T regs: Limiting collateral damage. J Clin Invest 2004;114:1372-1378.
19. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
20. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
21. Welsh TJ, Green RH, Richardson D et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23:8959-8967.
22. Abbas AK, Lichtman AH, Pillai S. Immunity to tumors. In: Abbas AK, Lichtman AH, Pillai S, eds. Cellular and Molecular Immunology, Sixth Edition. Philadelphia: Saunders Elsevier, 2007:397-417.
23. Engels EA, Cerhan JR, Linet MS et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: A case-control study. Am J Epidemiol 2005;162:1153-1161.
24. Grulich AE, Wan X, Law MG et al. Risk of cancer in people with AIDS. AIDS 1999;13:839-843.
25. Grulich AE, Wan X, Law MG et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000;14:133-140.
26. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005;37:409-419.
27. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:405-408.
28. Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60.
29. Diepstra A, van Imhoff GW, Karim-Kos HE et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101-3108.
30. Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 2002;169:2701-2711.
31. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521.
32. Lake RA, Robinson BWS. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005;5:397-405.
33. Lake RA, van der Most RG. A better way for a cancer cell to die. N Engl J Med 2006;354:2503-2504.
34. Nowak AK, Robinson BWS, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-4496.
35. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-4913.
36. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-1701.
37. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
38. Obeid M, Tesniere A, Panaretakis et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007;220:22-34.
39. Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025-3030.
40. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.
41. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245-1256.
42. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4491-4508.
43. Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614-1621.
44. Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005;23:8950-8958.
45. Correale P, Marsili S, Sabatino M et al. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncol Rep 2005;13:751-756.
46. Cartron G, Zhao-Yang L, Baudard M et al. Granulocyte-macrophage colony stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results of a phase II study. J Clin Oncol 2008;26:2725-2731.
47. Honkoop AH, Luykx-de Bakker SA, Hoekman K et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. The Oncologist 1999;4:106-111.
48. Pinedo HM, de Gruijl TD, van der Wall EW et al. Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors. The Oncologist 2000;5:497-500.
49. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. The Oncologist 2007;12(suppl 2):22-26.
50. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
51. Gregory SA, Trümper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: Is dose intensity an emerging paradigm for better outcomes? Ann Oncol 2005;16:1413-1424.
52. Tjan-Heijen VC, Wagener DJ, Postmus PE. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: Lessons to be drawn. Ann Oncol 2002;13:1519-1530.
53. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796.
54. Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
55. Gianni L. The "other" signaling of trastuzumab: Antibodies are immunocompetent drugs. J Clin Oncol 2008;26:1778-1780.